Alternative splicing;a checkpoint in neurodegeneration

Information

  • Research Project
  • 6485484
  • ApplicationId
    6485484
  • Core Project Number
    R43AG020884
  • Full Project Number
    1R43AG020884-01
  • Serial Number
    20884
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/15/2002 - 22 years ago
  • Project End Date
    8/31/2003 - 21 years ago
  • Program Officer Name
    WISE, BRADLEY C.
  • Budget Start Date
    5/15/2002 - 22 years ago
  • Budget End Date
    8/31/2003 - 21 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
  • Award Notice Date
    5/13/2002 - 22 years ago

Alternative splicing;a checkpoint in neurodegeneration

DESCRIPTION (provided by applicant): Activation of apoptosis, specifically the activation of caspases, leading to neuronal cell death may account for neurodegeneration in Alzheimer's disease. Since caspase-2, an initiator caspase, can act as a trigger to send a cell into apoptosis, its activity is not only regulated at the protein level but also at the level of alternative pre-mRNA splicing. Specific protein binding to an intronic sequence element, In 100, is critical for proper splice site usage. In 100 acts as a decoy acceptor site that causes exon skipping. We propose to develop and validate reagents for a high throughput assay that will be used to screen a compound library for small molecules that will disrupt the specific protein binding to Ini 00. A reporter gene will be added to a caspase-2 minigene construct to allow a convenient and cost effective screening. The proper regulation of this caspase-2 reporter minigene will be determined by comparison to the endogenous gene assayed in the same cells. Cell lines expressing the caspase-2 minigenes constructed in this Phase I application will be used to screen a small molecule library in the Phase II study focused on the development of an anti-neurodegenerative therapeutic.

IC Name
NATIONAL INSTITUTE ON AGING
  • Activity
    R43
  • Administering IC
    AG
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    99948
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    866
  • Ed Inst. Type
  • Funding ICs
    NIA:99948\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MESSAGE PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    MALVERN
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    19355
  • Organization District
    UNITED STATES